Live tape
Top 8, mentions 7d2,137GOOGL453 mentions▲ +0.06NVDA345 mentions▲ +0.07META271 mentions▲ +0.05QQQ266 mentions▲ +0.09SPY256 mentions▲ +0.04AAPL193 mentions▲ +0.04MSFT178 mentions▲ +0.06TSLA175 mentions▲ +0.06

Equity · Healthcare

AORT

Artivion, Inc. · NYSE

$23 −4.17% 1D Finazon · prior-day close · Sep 18, 2026
Price · Chart
Our own end-of-day closes 63 sessions
$30 $15 22 Jun 18 Sep

The line runs $20 on 22 June through $23 on 18 September, on a scale from $15 to $30. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of AORT over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 63 sessions over that window: $20 on 22 June 2026 through $23 on 18 September 2026.

Market cap $1.1B
52-week range $20 – $48
Avg volume 44.7K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 20, 2026

AORT insider trades

SEC Form 4 · last 90 days · newest reported trade 10 Sep 2026
Open-market buys 0
Open-market sells 7
Net sold $2.60M
Non-trade filings 0
Date Insider Type Shares Value
10 Sep 2026 GREEN ANDREW M SVP, Regulatory and Quality Sell 11,480 $287K
03 Sep 2026 GREEN ANDREW M SVP, Regulatory and Quality Sell 1,493 $39K
02 Sep 2026 GREEN ANDREW M SVP, Regulatory and Quality Sell 6,510 $177K
19 Aug 2026 Mackin James P President & CEO Sell 70,000 $2.03M
14 Aug 2026 Berry Lance A EVP, COO, CFO & Treasurer Sell 715 $20K
14 Aug 2026 GREEN ANDREW M SVP, Regulatory and Quality Sell 616 $18K
12 Aug 2026 Holloway Jean F SVP, General Counsel Sell 977 $28K

AORT reported financials

SEC EDGAR XBRL

AORT reported revenue of $441.3M for the fiscal year ended 31 Dec 2025. Net income over the same period was $9.8M.

Figure Reported Period
Revenue $441.3M 31 Dec 2025 fiscal year
Net income $9.8M 31 Dec 2025 fiscal year
Diluted EPS $0.21 31 Dec 2025 fiscal year
Total assets $1.1B 30 Jun 2026 at period end
Total equity $445.6M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

AORT earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.28 —
31 Mar 2026 Q1 2026 $0.03 —
31 Dec 2025 FY 2025 $0.21 —
30 Sep 2025 Q3 2025 $0.13 —
30 Jun 2025 Q2 2025 $0.03 —
31 Mar 2025 Q1 2025 $-0.01 —
31 Dec 2024 FY 2024 $-0.32 —
30 Sep 2024 Q3 2024 $-0.05 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

AORT institutional holders

SEC Form 13F

6 of the 45 institutional funds we track reported a AORT position for the quarter ended 30 Jun 2026 — a combined $47.6M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Citadel Advisors Added +1,067.8% shares 827,594 $18.6M
D. E. Shaw & Co. Added +6,614.9% shares 438,216 $9.8M
Two Sigma Investments Trimmed −46.6% shares 387,279 $8.7M
Balyasny Asset Management Added +1,192.7% shares 382,051 $8.6M
Renaissance Technologies New position 67,827 $1.5M
AQR Capital Management Held (±25%) −21.4% shares 14,383 $323K
Man Group Exited
Marshall Wace Exited

Source: SEC EDGAR 13F filings

AORT fails-to-deliver

SEC CNS data

On 28 Aug 2026, 3,539 shares of AORT failed to deliver (about $94K).

Settlement date Shares failed Notional % of shares out
28 Aug 2026 3,539 $94K 0.007%
26 Aug 2026 34 $897 <0.001%
20 Aug 2026 165 $5K <0.001%
19 Aug 2026 409 $12K 0.001%
14 Aug 2026 153 $4K <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in AORT

STOCK Act disclosures

The most recent congressional trade disclosed in AORT is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 20 Aug 2026.

Date Member Type Amount
20 Aug 2026 filed 10 Sep 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K

Source: U.S. House of Representatives financial disclosures